grow your investment.
Anthem Biosciences IPO: Listing Day Strategy, Business Analysis.
Today’s spotlight features Bajaj Finance – and believThe Anthem Biosciences IPO allotment status is already out, and many investors are feeling disappointed after not receiving any shares. But like every IPO journey, the game is not over yet. In this article, we will cover in detail what investors should do next, whether to buy on listing day, and whether Anthem Biosciences is worth holding for the long term. So, if you’ve received allotment or missed out, this guide will help you plan your next move.e it or not, for all the right reasons. The company has announced that its board of directors will be meeting on April 29, 2025, to discuss key corporate actions such as interim dividend, stock split and bonus share issuance. Additionally, the financial results for the March quarter will also be presented. But what’s most interesting is that Bajaj Finance has had a stellar performance in 2025, delivering returns of around 35% so far, increasing investor wealth by over ₹1.5 lakh crore.
Anthem Biosciences IPO Overview
Anthem Biosciences Limited is a Bangalore-based pharmaceutical company that operates in the CRDMO (Contract Research, Development, and Manufacturing Organization) segment. The company manufactures dietary supplements, animal nutrition products, enzymes, and Active Pharma Ingredients (APIs). The CRDMO model allows Anthem Biosciences to work on a contract basis for large pharma companies like Sun Pharma and others.
Price Band: ₹540 to ₹570 per share
Issue Size: Over ₹3,000 crore
Allotment Price: ₹570 per share
Published July 21, 2025.
IPO Subscription Details
Anthem Biosciences IPO witnessed strong demand from investors:
QIB (Qualified Institutional Buyers): 192x subscription
Overall Subscription: Approx. 200x
Considering the large issue size (₹3,000 crore), such a high QIB subscription is a positive sign. Institutions investing heavily reflects confidence in the company’s future potential.
GMP and Listing Day Expectation
The current GMP (Grey Market Premium) is around ₹140 per share, indicating an expected 25% listing gain. Based on this, shares might list near ₹700 levels.
Expected Listing Price: ₹700 approximately
Potential Listing Gain: 25%
However, GMP is dynamic and changes quickly based on market sentiment.
Anthem Biosciences Business Model
Anthem Biosciences focuses on:
Dietary Supplements: Protein powders, creatine, vitamins, and minerals
Animal Nutrition
Digestive Enzymes
Active Pharmaceutical Ingredients (APIs)
CRDMO Services: Contract-based research, development, and manufacturing
Its operations span two key manufacturing sites in Bangalore.
CRDMO Sector Potential
Current Market Size (2025): $3 to $3.5 billion
Expected Market Size (2035): $25 billion
Projected CAGR (Next 10 Years): 22%
The sector’s growth potential supports long-term investment opportunities.
Anthem Biosciences Financial Analysis
| Financial Year | Revenue (₹ crore) | Net Profit (₹ crore) |
|---|---|---|
| 2021 | 1,133 | 271 |
| 2022 | 1,280 | 405 |
| 2023 | 1,483 | 450 |
| 2024 | 2,015 | 450 |
Assets: Grew from ₹1,600 crore (2021) to ₹2,800 crore (2024)
EBITDA Margin: 37%
PAT Margin: 22%
ROCE: 34%
ROE: 26%
Market Cap: Approx. ₹32,000 crore (post-IPO)
Price-to-Earnings (P/E) Ratio: 63 (at ₹570), expected to rise post-listing to 78-80
Competitor Comparison: Suven Pharmaceuticals (S Life Sciences)
Suven’s P/E ratio is 100.
Suven is smaller compared to Anthem Biosciences but operates in the same CRDMO space.
Anthem’s valuation appears reasonable considering sector potential and peer comparison.
Listing Day Strategy
For Allotment Holders
If you’re a serial IPO investor, booking 25%-30% profit on listing day makes sense.
Many IPOs are lined up, like IndiQube, NSDL, Hero FinCorp, and Brigade Hotels. Capital recycling is wise.
However, if you’re a long-term investor with at least a 6-month horizon, holding makes sense due to sector growth.
For Non-Allottees (Fresh Buyers)
Avoid buying on listing day if your horizon is short-term. Wait for price correction.
If you’re willing to hold for 6 months to 1 year, fresh buying is possible post-listing when price stabilizes.
Keep an eye on quarterly results to validate growth trajectory.
Risks to Consider
India-US trade policies and pharma tariffs may impact the CRDMO sector.
Market volatility could affect near-term returns.
Conclusion
The Anthem Biosciences IPO is backed by strong fundamentals, a scalable CRDMO business model, and institutional confidence. Listing gains are likely, but long-term investors with patience could benefit significantly from the sector’s growth trajectory.
If you’ve received the allotment, evaluate your risk appetite: book profits early or hold for a potential breakout. For fresh buyers, wait for post-listing stability before entering.
Recommended
On-Campus Resources to Note
Common on-campus resources include tutoring, writing centers, career services...
By Sarah Wood
Mental Health on College Campuses
About 70% of students have struggled with mental health since starting college...
By Sarah Wood
Mental Health on College Campuses
About 70% of students have struggled with mental health since starting college...
By Sarah Wood
Mental Health on College Campuses
About 70% of students have struggled with mental health since starting college...
By Sarah WoodRelated Articles
Add Your Head........
Add Your Head........
Add Your Head........